The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective, observational registry of branded imatinib (IM) and nilotinib (NIL) exposure in pregnant women: Voluntary post-authorization safety study.
Matthews Juma
Employment or Leadership Position - Novartis
Solveig Ericson
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Dawn Fun Eng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sandip Acharya
Employment or Leadership Position - Novartis
Darshan Wariabharaj
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tina Owugah
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Bettine Avenia
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Oleg Zernovak
Employment or Leadership Position - Novartis
Stock Ownership - Novartis